A study on mice found that the anti-angiogenesis drug cilengitide, which is designed to impede the growth of tumor blood vessels, stimulated the development of cancers when given at low doses. The research could help improve the effectiveness of cancer treatments such as Avastin and Sutent, cancer experts said.

Full Story:

Related Summaries